Cargando…
Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases
INTRODUCTION: Autoimmune diseases include a diverse and complex group of pathologies with a broad clinical spectrum due to the production of autoantibodies, which generates multisystemic compromise. Therapeutic plasma exchange (TPE) is a good additive treatment for immunosuppression due to its actio...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432729/ https://www.ncbi.nlm.nih.gov/pubmed/30984421 http://dx.doi.org/10.1155/2019/5350960 |
_version_ | 1783406190557921280 |
---|---|
author | Aguirre-Valencia, David Naranjo-Escobar, Juan Posso-Osorio, Iván Macía-Mejía, María Carmenza Nieto-Aristizábal, Ivana Barrera, Tatiana Obando, María Alejandra Tobón, Gabriel J. |
author_facet | Aguirre-Valencia, David Naranjo-Escobar, Juan Posso-Osorio, Iván Macía-Mejía, María Carmenza Nieto-Aristizábal, Ivana Barrera, Tatiana Obando, María Alejandra Tobón, Gabriel J. |
author_sort | Aguirre-Valencia, David |
collection | PubMed |
description | INTRODUCTION: Autoimmune diseases include a diverse and complex group of pathologies with a broad clinical spectrum due to the production of autoantibodies, which generates multisystemic compromise. Therapeutic plasma exchange (TPE) is a good additive treatment for immunosuppression due to its action over the autoantibodies. OBJECTIVES: To describe the main clinical characteristics and outcomes of patients with systemic lupus erythematosus and other systemic autoimmune diseases managed with TPE. METHODOLOGY: This descriptive retrospective study enrolled patients with systemic autoimmune diseases who received TPE. RESULTS: In total, 66 patients with a median age of 33.5 years (24-53 years) were included; the majority were females [n=51 (77.27%)]. Forty (60.61%) patients were diagnosed with systemic lupus erythematosus. In these cases, the main indication for TPE was diffuse alveolar hemorrhage (DAH; n=20, 30.3%) and neurolupus (n=9, 13.6%). No TPE-related deaths occurred, and the main complication was hemorrhage, without significant differences among the four types of TPE solutions used. The overall outcome was improvement in 41 (62.12%) patients. CONCLUSION: TPE is safe and effective in patients with severe manifestations of autoimmune diseases. |
format | Online Article Text |
id | pubmed-6432729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-64327292019-04-14 Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases Aguirre-Valencia, David Naranjo-Escobar, Juan Posso-Osorio, Iván Macía-Mejía, María Carmenza Nieto-Aristizábal, Ivana Barrera, Tatiana Obando, María Alejandra Tobón, Gabriel J. Autoimmune Dis Research Article INTRODUCTION: Autoimmune diseases include a diverse and complex group of pathologies with a broad clinical spectrum due to the production of autoantibodies, which generates multisystemic compromise. Therapeutic plasma exchange (TPE) is a good additive treatment for immunosuppression due to its action over the autoantibodies. OBJECTIVES: To describe the main clinical characteristics and outcomes of patients with systemic lupus erythematosus and other systemic autoimmune diseases managed with TPE. METHODOLOGY: This descriptive retrospective study enrolled patients with systemic autoimmune diseases who received TPE. RESULTS: In total, 66 patients with a median age of 33.5 years (24-53 years) were included; the majority were females [n=51 (77.27%)]. Forty (60.61%) patients were diagnosed with systemic lupus erythematosus. In these cases, the main indication for TPE was diffuse alveolar hemorrhage (DAH; n=20, 30.3%) and neurolupus (n=9, 13.6%). No TPE-related deaths occurred, and the main complication was hemorrhage, without significant differences among the four types of TPE solutions used. The overall outcome was improvement in 41 (62.12%) patients. CONCLUSION: TPE is safe and effective in patients with severe manifestations of autoimmune diseases. Hindawi 2019-03-11 /pmc/articles/PMC6432729/ /pubmed/30984421 http://dx.doi.org/10.1155/2019/5350960 Text en Copyright © 2019 David Aguirre-Valencia et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Aguirre-Valencia, David Naranjo-Escobar, Juan Posso-Osorio, Iván Macía-Mejía, María Carmenza Nieto-Aristizábal, Ivana Barrera, Tatiana Obando, María Alejandra Tobón, Gabriel J. Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases |
title | Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases |
title_full | Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases |
title_fullStr | Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases |
title_full_unstemmed | Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases |
title_short | Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases |
title_sort | therapeutic plasma exchange as management of complicated systemic lupus erythematosus and other autoimmune diseases |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432729/ https://www.ncbi.nlm.nih.gov/pubmed/30984421 http://dx.doi.org/10.1155/2019/5350960 |
work_keys_str_mv | AT aguirrevalenciadavid therapeuticplasmaexchangeasmanagementofcomplicatedsystemiclupuserythematosusandotherautoimmunediseases AT naranjoescobarjuan therapeuticplasmaexchangeasmanagementofcomplicatedsystemiclupuserythematosusandotherautoimmunediseases AT possoosorioivan therapeuticplasmaexchangeasmanagementofcomplicatedsystemiclupuserythematosusandotherautoimmunediseases AT maciamejiamariacarmenza therapeuticplasmaexchangeasmanagementofcomplicatedsystemiclupuserythematosusandotherautoimmunediseases AT nietoaristizabalivana therapeuticplasmaexchangeasmanagementofcomplicatedsystemiclupuserythematosusandotherautoimmunediseases AT barreratatiana therapeuticplasmaexchangeasmanagementofcomplicatedsystemiclupuserythematosusandotherautoimmunediseases AT obandomariaalejandra therapeuticplasmaexchangeasmanagementofcomplicatedsystemiclupuserythematosusandotherautoimmunediseases AT tobongabrielj therapeuticplasmaexchangeasmanagementofcomplicatedsystemiclupuserythematosusandotherautoimmunediseases |